Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aeterna Zentaris has received patent from European Patent Office (EPO) for ghrelin agonist, AEZS-130, to diagnose growth hormone deficiency (GHD) in a human or animal subject.
Subscribe to our email newsletter
AEZS-130 patent came into effect from 19 September 2012 and will be valid till 19 February 2027.
Aeterna Zentaris president and CEO Juergen Engel said the patent in Europe and US are key elements to ensure the protection of AEZS 130 to diagnose GHD.
”We now look forward to filing a New Drug Application in the near future in the U.S. for AEZS-130, which could become the first approved oral diagnostic test for adults with GHD," Engel added.
AEZS-130 is a new oral active small molecule, which stimulates the secretion of growth hormone.
Adult Growth Hormone Deficiency affects nearly 35,000 US citizens along with 6,000 new cases each year.